Biocompatible superparamagnetic core-shell nanoparticles for potential use in hyperthermia-enabled drug release and as an enhanced contrast agent
Source abstract
Abstract
Abstract Superparamagnetic iron oxide nanoparticles (SPIONs) and core-shell type nanoparticles, consisting of SPIONs coated with mesoporous silica and/or lipid, were synthesised and tested for their potential theranostic applications in drug delivery, magnetic hyperthermia and as a contrast agent. Transmission Electron Microscopy (TEM) confirmed the size of bare and coated SPIONs was in the range of 5–20 nm and 100–200 nm respectively. The superparamagnetic nature of all the prepared nanomaterials as indicated by Vibrating Sample Magnetometry (VSM) and their heating properties under an AC field confirm their potential for hyperthermia applications. Scanning Column Magnetometry (SCM) data showed that extrusion of bare-SPION (b-SPION) dispersions through a 100 nm polycarbonate membrane significantly improved the dispersion stability of the sample. No sedimentation was apparent after 18 h compared to a pre-extrusion estimate of 43% settled at the bottom of the tube over the same time. Lipid coating also enhanced dispersion stability. Transversal relaxation time (T2) measurements for the nanoparticles, using a bench-top relaxometer, displayed a significantly lower value of 46 ms, with a narrow relaxation time distribution, for lipid silica coated SPIONs (Lip-SiSPIONs) as compared to that of 1316 ms for the b-SPIONs. Entrapment efficiency of the anticancer drug, Doxorubicin (DOX) for Lip-SPIONs was observed to be 35% which increased to 58% for Lip-SiSPIONs. Moreover, initial in-vitro cytotoxicity studies against human breast adenocarcinoma, MCF-7 cells showed that % cell viability increased from 57% for bSPIONs to 82% for Lip-SPIONs and to 87% for Lip-SiSPIONs. This suggests that silica and lipid coatings improve the biocompatibility of bSPIONs significantly and enhance the suitability of these particles as drug carriers. Hence, the magnetic nanomaterials prepared in this work have potential theranostic properties as a drug carrier for hyperthermia cancer therapy and also offer enhancement of contrast agent efficacy and a route to a significant increase in dispersion stability.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Characterization and Applications of Magnetic Nanoparticles · Iron oxide chemistry and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (80)
Show source-provided references
1. Nanoparticles and cancer therapy: perspectives for application of nanoparticles in the treatment of cancers10.1002/jcp.29126 ↗
2. Magnetic analysis of commercial hematite, magnetite, and their mixtures10.1063/1.5006474 ↗
3. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles10.1515/dmpt-2018-0032 ↗
4. Amreddy · 2018
5. Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast10.1038/nnano.2010.203 ↗
6. Synthesis, characterization and in vitro toxicity evaluation of doxorubicin-loaded magnetoliposomes on MCF-7 breast cancer cell line10.1016/j.jddst.2019.101447 ↗
7. Stability of polymersomes prepared by size exclusion chromatography and extrusion10.1016/j.colsurfa.2016.07.032 ↗
8. Blanco-andujar · 2018
9. Dual T1/T2 MRI contrast agent based on hybrid SPION@coordination polymer nanoparticles10.1039/C5RA17661A ↗
10. Advances in magnetic nanoparticles for biomedical applications10.1002/adhm.201700845 ↗
11. Qualitative analysis by online nuclear magnetic resonance using Carr-Purcell-Meiboom-Gill sequence with low refocusing flip angles10.1016/j.talanta.2010.12.033 ↗
12. Water-mediated nanostructures for enhanced MRI: impact of water dynamics on relaxometric properties of Gd-DTPA10.7150/thno.27313 ↗
13. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine10.1016/j.addr.2019.04.008 ↗
14. Nanomaterial applications in photothermal therapy for cancer10.3390/ma12050779 ↗
15. Superparamagnetic and single-domain threshold sizes in magnetite10.1029/JB078i011p01780 ↗
16. Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents10.2147/IJN.S76501 ↗
17. Foldamers as anticancer therapeutics: targeting protein–protein interactions and the cell membrane10.1002/cbic.201500188 ↗
18. Development of a novel, multifunctional, membrane-interactive pyridinium salt with potent anticancer activity10.1016/j.bmcl.2014.05.087 ↗
19. Doxorubicin induces drug resistance and expression of the novel CD44st via NF-kappa B in human breast cancer MCF-7 cells10.3892/or.2014.3131 ↗
20. Static and dynamic magnetic properties of spherical magnetite nanoparticles10.1063/1.1599959 ↗
21. Light/magnetic hyperthermia triggered drug released from multi-functional thermo-sensitive magnetoliposomes for precise cancer synergetic theranostics10.1016/j.jconrel.2017.04.028 ↗
22. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications10.1016/j.biomaterials.2004.10.012 ↗
23. State of the art of stimuli-responsive liposomes for cancer therapy
24. Magnetic particle hyperthermia: nanoparticle magnetism and materials development for cancer therapy10.1088/0953-8984/18/38/S26 ↗
25. Clustering superparamagnetic iron oxide nanoparticles produces organ-targeted high-contrast magnetic resonance images10.2217/nnm-2018-0370 ↗
26. Tailored functionalization of iron oxide nanoparticles for MRI, drug delivery, magnetic separation and immobilization of biosubstances10.1016/j.biotechadv.2015.02.003 ↗
27. Observing the colloidal stability of iron oxide nanoparticles in situ10.1039/C9NR03709H ↗
28. Structure and magnetic properties of silica-coated magnetite-nanoparticle composites10.1088/2053-1591/ab29af ↗
29. Functionalized Superparamagnetic Iron Oxide Nanoparticles (SPIONs) as platform for the targeted multimodal tumor therapy10.3389/fonc.2019.00059 ↗
30. Nanoparticles: properties, applications and toxicities10.1016/j.arabjc.2017.05.011 ↗
31. A new method for the identification and quantification of magnetite–maghemite mixture using conventional x-ray diffraction technique10.1016/j.talanta.2012.03.001 ↗
32. Cancer hyperthermia using magnetic nanoparticles10.1002/biot.201100045 ↗
33. In vitro application of paclitaxel loaded magnetoliposomes for combined chemotherapy and hyperthermia10.1016/j.colsurfb.2012.02.029 ↗
34. Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery10.1016/j.addr.2011.03.008 ↗
35. Theranostics based on liposome: looking back and forward10.1007/s13139-019-00603-z ↗
36. Understanding the nano-bio interfaces: lipid-coatings for inorganic nanoparticles as promising strategy for biomedical applications10.3389/fchem.2019.00343 ↗
37. Tunable self-assembled peptide structure: a novel approach to design dual-use biological agents10.1016/j.matpr.2017.01.190 ↗
38. Room temperature co-precipitation synthesis of magnetite nanoparticles in a large pH window with different bases10.3390/ma6125549 ↗
39. The observed linearity and detection response of magnetic fluid concentration magnetometry-a theoretical and experimental description10.1109/TMAG.2013.2245867 ↗
40. Delivering safer immunotherapies for cancer10.1016/j.addr.2017.05.011 ↗
41. Structural and magnetic properties of silica-coated magnetite nanoaggregates10.1016/j.physb.2019.08.007 ↗
42. Size dependent heat generation of magnetite nanoparticles under AC magnetic field for cancer therapy10.1186/1477-044X-6-4 ↗
43. Preparation of magnetic nanoparticles with large specific loss power for heating applications10.1016/j.jmmm.2004.11.005 ↗
44. Cell membrane coated nanoparticles: next-generation therapeutics10.2217/nnm-2017-0225 ↗
45. The effect of patient-to-patient variability in drug response on combination cancer therapies, from 1961 to today10.1200/JCO.2018.36.15_suppl.e14552 ↗
46. In vitro hyperthermia with improved colloidal stability and enhanced SAR of magnetic core/shell nanostructures10.1016/j.msec.2015.10.064 ↗
47. Patil-sen · 2018
48. Patil-sen · 2019
49. A monolayer phase behaviour study of phosphatidylinositol, phosphatidylinositol 4-monophosphate and their binary mixtures with distearoylphosphatidylethanolamine10.1039/B314615B ↗
50. Nanoparticle-based paramagnetic contrast agents for magnetic resonance imaging10.1155/2019/1845637 ↗
51. Superparamagnetic nanoparticle ensembles10.1016/j.spmi.2010.01.009 ↗
52. Combined hyperthermia and chemotherapy as a synergistic anticancer treatment10.1007/s40005-019-00431-5 ↗
53. pH- and thermosensitive thin lipid layer coated mesoporous magnetic nanoassemblies as a dual drug delivery system towards thermochemotherapy of cancer10.1016/j.actbio.2014.04.011 ↗
54. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy10.1016/j.jconrel.2009.10.002 ↗
55. Nanoparticle-triggered release from lipid membrane vesicles10.1016/j.nbt.2014.12.002 ↗
56. Delivery technologies for cancer immunotherapy10.1038/s41573-018-0006-z ↗
57. Magnetoliposomes as carriers for promising antitumor thieno[3,2-b]pyridin-7-arylamines: photophysical and biological studies10.1039/C7RA00447H ↗
58. Heating magnetic fluid with alternating magnetic field10.1016/S0304-8853(02)00706-0 ↗
59. Rovers · 2010
60. A microfluidic platform to design crosslinked Hyaluronic Acid Nanoparticles (cHANPs) for enhanced MRI10.1038/srep37906 ↗
61. Preparation and characterization of extruded magnetoliposomes10.1016/j.ijpharm.2007.06.047 ↗
62. Advances and challenges of liposome assisted drug delivery10.3389/fphar.2015.00286 ↗
63. The fabrication and characterization of stable core-shell superparamagnetic nanocomposites for potential application in drug delivery10.1063/1.4917264 ↗
64. Drug-loaded liposome-capped mesoporous core-shell magnetic nanoparticles for cellular toxicity study10.2217/nnm-2016-0248 ↗
65. Recent advances in metal nanoparticles in cancer therapy10.1080/1061186X.2017.1400553 ↗
66. An assessment of progress in cancer control10.3322/caac.21460 ↗
67. Magnetoliposomes: versatile innovative nanocolloids for use in biotechnology and biomedicine10.2217/17435889.4.2.177 ↗
68. Surface characteristics of magnetite in aqueous suspension10.1006/jcis.1997.5239 ↗
69. T1–T2 Dual-modal MRI contrast agents based on superparamagnetic iron oxide nanoparticles with surface attached gadolinium complexes10.1007/s11051-014-2678-6 ↗
70. Magnetic field-assisted selective delivery of doxorubicin to cancer cells using magnetoliposomes as drug nanocarriers10.1088/1361-6528/ab19d3 ↗
71. Effect of the distribution of anisotropy constants on hysteresis losses for magnetic hyperthermia applications10.1063/1.4824649 ↗
72. Mechanisms of hyperthermia in magnetic nanoparticles10.1088/0022-3727/46/31/312001 ↗
73. Hybrid core shell nanoparticles entrapping Gd-DTPA and (18)F-FDG for simultaneous PET/MRI acquisitions10.2217/nnm-2017-0110 ↗
74. Hybrid core-shell (HyCoS) nanoparticles produced by complex coacervation for multimodal applications10.1038/srep45121 ↗
75. Nanoparticles for hyperthermic therapy: synthesis strategies and applications in glioblastoma10.2147/IJN.S57501 ↗
76. Promising effects of nanomedicine in cancer drug delivery10.1080/1061186X.2017.1377207 ↗
77. Nanomaterials for cancer precision medicine10.1002/adma.201705660 ↗
78. Mesoporous silica/organosilica nanoparticles: synthesis, biological effect and biomedical application10.1016/j.mser.2019.01.001 ↗
79. Magnetite ferrofluid with high specific absorption rate for application in hyperthermia10.1016/j.jmmm.2006.11.179 ↗
80. Surface modification of magnetic iron oxide nanoparticles10.3390/nano8100810 ↗